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Background: Patients with diabetes mellitus (DM) have an increased risk for periprocedural complications and
adverse cardiac events after percutaneous coronary intervention. We addressed the potential for coronary
microvascular obstruction and restenosis in patients with and without DM undergoing stenting for saphenous vein
bypass graft (SVG) stenosis under protection with a distal occlusion/aspiration device.
Methods: SVG plaque volume and composition were analyzed using intravascular ultrasound before stent
implantation. Percent diameter stenosis was determined from quantitative coronary angiography before,
immediately after and 6 months after stent implantation. Coronary aspirate was retrieved during stent implantation
and divided into particulate debris and plasma. Total calcium, several vasoconstrictors, and tumor necrosis factor
(TNF)α in particulate debris and coronary aspirate plasma were determined.
Results: Patients with and without DM had similar plaque volume, but larger necrotic core and greater particulate
debris release in patients with than without DM (20.3±2.7 vs. 12.7±2.6% and 143.9±19.3 vs. 75.1±10.4 mg, P<0.05).
The TNFα concentration in particulate debris and coronary aspirate plasma was higher in patients with than
without DM (15.9±6.6 vs. 5.1±2.4 pmol/mg and 2.2±0.7 vs. 1.1±0.2 pmol/L, P<0.05), whereas total calcium and
vasoconstrictors were not different. Patients with DM had a greater percent diameter stenosis 6 months after stent
implantation than those without DM (22.17±5.22 vs. 6.34±1.11%, P<0.05). The increase in TNFα immediately after
stent implantation correlated with restenosis 6 months later (r=0.69, P<0.05).
Conclusion: In diabetics, particulate debris and coronary aspirate plasma contained more TNFα, which might reflect
the activity of the underlying atherosclerotic process.
Trial registration: URL: http://www.clinicaltrials.gov/ct2/results?term=NCT01430884; unique identifier: NCT01430884
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Interventional plaque rupture induces the release not
only of particulate debris, but also of soluble vasocon-
strictor, thrombogenic and inflammatory substances
from the lesion. Both, particulate debris as well as sol-
uble substances, contribute to impair microvascular
coronary perfusion [1,2] with typical consequences:
microinfarcts with a subsequent inflammatory reaction
[3], arrhythmias, contractile dysfunction, and impaired
coronary reserve [4]. We have previously reported the* Correspondence: petra.kleinbongard@uk-essen.de
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reproduction in any medium, provided the orrelease of serotonin, thromboxane (Tx)A2, and tumor
necrosis factor (TNF)α into the coronary aspirate
retrieved from patients during stenting of stenotic sa-
phenous vein bypass grafts (SVG) [5-8].
Diabetes mellitus (DM) is associated with a higher risk
for periprocedural complications and more adverse car-
diac events after percutaneous coronary interventions
(PCI) [9-12], including stent implantation into SVGs
[13,14]. Patients with DM have more necrotic core in
coronary atherosclerosis of their native coronary arteries
than patients without DM [15-18]. However, the impact
of DM on microvascular obstruction and on restenosis
after stent implantation into SVGs is not really clear. In
type 2 diabetes patients undergoing elective stenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Baars et al. Cardiovascular Diabetology 2013, 12:12 Page 2 of 10
http://www.cardiab.com/content/12/1/12implantation into native coronary arteries, the number
of microemboli visualized and counted as high-intensity
transient signals with a Doppler wire during elective PCI
is increased [19]. The incidence of restenosis at 6 months
after stent implantation into native coronary arteries is
higher in patients with than in those without DM [10].
In contrast, in patients undergoing elective stent im-
plantation into stenotic SVGs, the incidence of no-
reflow and of restenosis was similar between those with
and without DM [13]. DM is associated with both, sys-
temic inflammation and atherosclerosis [20-22]. Vari-
ous cytokines and inflammatory mediators (IFN-γ,
IL-1, IL-6, TNFα etc.) contribute to the pathogenesis
of inflammation observed in atherosclerosis [23-25].
Among these cytokines, TNFα has already been
reported to be localized in human atheromatous pla-
ques [26], and to contribute to plaque progression,
destabilization, and rupture [27], as well as to pro-
gression of restenosis [28].
In the present study, we took advantage of the use of
an aspiration device during stent implantation into SVGs
and analyzed both, the particulate debris and the soluble
vasoconstrictor (catecholamines, endothelin, serotonin,
Tx B2, tissue factor) and inflammatory mediators (TNFα
as a prototype of inflammatory cytokines [29]), in the
retrieved coronary aspirate biochemically and by com-
parison to intravascular ultrasound (IVUS) imaging [30]




Symptomatic patients with stable angina pectoris and a
flow-limiting SVG stenosis (n=40) were recruited. The
study was conducted in accordance with the ethical
guidelines of the Declaration of Helsinki 1975, and the
investigation was approved by the Institutional Review
Board (GZ.: 07–3387) and registered at ClinicalTrials.
gov (NCT01430884). All patients gave informed consent
prior to their inclusion in the study. Using a position
statement of the American Diabetes Association on
Diagnosis and Classification of DM [31], patients were
classified according to their hemoglobin (Hb)A1c-value
and their use of antidiabetic medications (with DM:
HbA1c ≥ 6.5% and with use of antidiabetic medications
vs. without DM: HbA1c < 5.7% and without use of anti-
diabetic medications).
Quantitative coronary angiography
Patients were on aspirin (100 mg/day) and received
10.000 I.U. heparin intravenously. 17 patients each with
and without DM were on clopidogrel (75 mg/day). Cor-
onary angiography was performed using the femoral ap-
proach and 6F or 8F guiding catheters. Stenosis severitywas quantified using off-line caliper measurements
(QCA-MEDISR, Leiden, NL) [32], and thrombolysis in
myocardial infarction (TIMI) flow was measured before
and after stent implantation [33]. Minimal lumen diam-
eter and reference diameter were determined before, im-
mediately after, and at follow-up 6 months after stent
implantation, and the percent diameter stenosis was
calculated.
IVUS and virtual histology (VH) analysis
IVUS was performed before and after stent implantation
with a commercially available electronic IVUS catheter
(Eagle-EyeTM 20 MHz catheter and R-100 pullback de-
vice, Volcano Corporation, Rancho Cordova, CA, USA).
The site and the length of the target lesion before stent
implantation were retrospectively identified after stent
implantation from landmarks in the vascular profile
[34,35]. Plaque composition was categorized with VH
using a customized software (pcVHTM2.1, Volcano
Corp.). All detected plaque components (fibrotic, fibro-
fatty, necrotic core, dense calcium) were presented as a
fraction of total plaque volume (%) [35].
Interventional procedure
Implantation of balloon-expandable bare metal stents
was performed with direct stenting without prior dilata-
tion/debulking and a stent-to-vessel diameter ratio of
1:1.15, because stenting with predilatation eventually
increases plaque mobilisation and debris embolism [36].
To prevent microembolization, a distal balloon occlusion
extraction device (GuardWireR Temporary Occlusion &
Aspiration System; Medtronic Inc., Minneapolis, MN
USA) [37] was used. Before stent implantation, the bal-
loon of the device was inflated at 2 atm with contrast
agent. After stent implantation, the catheter with the
stent-balloon was removed, and the aspiration catheter
was loaded onto the monorail GuardWireR. During slow
withdrawal of the aspiration catheter, the blood column
was retrieved. Then, the balloon was deflated. After PCI
patients were loaded with 600 mg of clopidogrel and
medication was continued at a dose of 75 mg/day for
the next 4 weeks.
Coronary arterial blood and coronary aspirate
Coronary arterial blood was obtained through the
respective aspiration catheter (10 mL into Heparin S-
Monovette, SARSTEDT AG & Co, Nümbrecht, Germany)
distal to the lesion before stent implantation and served as
control. Coronary aspirate (between 10 and 20 mL) was
filtered ex vivo through a 40 μm mesh filter. The aspirate
dilution by contrast agent was corrected for by reference
to the hematocrit. Visible particulate debris was retained
on the filter and weighed.
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were immediately centrifuged (800 g, 10 min, 4°C). Both,
particulate debris and plasma samples were quickly
frozen in liquid nitrogen and stored at −80°C until fur-
ther use.Total calcium, vasoconstrictors, tissue factor, TNFα, C
reactive protein (CRP), and troponin I
Total calcium concentration (sum of ionized and bound/
complexed calcium) was measured in coronary arterial
and aspirate plasma and in particulate debris after ex-
traction with HCl by atomic absorption spectrophotom-
etry [38].
The serotonin concentration in particulate debris and
plasma was measured using an enzyme immunometric
assay kit (Assay Designs, Michigan, USA). The TxB2
concentration in particulate debris and plasma was
determined using the ACE™ enzyme immunoassay (Cay-
man Chemical Company, Ann Arbor, USA). The TNFα
concentration in particulate debris and plasma was
determined using a sandwich enzyme immunoassay
(Cayman Chemical Company, Ann Arbor, USA). The
plasma concentration of endothelin was detected using
the immunometric endothelin assay kit (ACE™ enzyme
immunoassay, Cayman Chemical Company, Ann Arbor,
USA). The plasma concentrations of epinephrine
and norepinephrine were determined by HPLC with
electrochemical detection (EC 41.000 Chromsystems,
München, Germany) using a kit and a reverse phase
analytical column (Chromsystems, München, Germany).
To determine plasma tissue factor concentration the
IMUBIND Tissue Factor Elisa Kit was used, as described
by the manufacturer (American diagnostica inc, Stamford,
USA).
Peripheral venous blood was taken before and between
6 and 48 h after stent implantation. Serum CRP was
determined in peripheral venous blood taken before
stent implantation using an immunometric assay kit
(ADVIA Clinical Chemistry System, Siemens, Tarrytown,
USA). Serum troponin I was measured using a specific
2-side immunoassay detected with the DimensionR RxL
MaxR Integrated System (Dimension Flex, Dade Behring
GmbH, Marburg; and Siemens, Eschborn, Germany)
[7,35].Vasomotor bioassay
Human coronary arteries and rat mesenteric arteries are
characterized by a comparable receptor arrangement for
serotonin and TxA2 [5,7,8]. Therefore, we used rat mes-
enteric arteries with intact and denuded endothelium
(+E/–E). Segments of 2 mm length were mounted in a
Mulvany myograph and equilibrated with Krebs-
Henseleit buffer. After verification of functionalityvessels were incubated with coronary arterial and aspir-
ate plasma, which was diluted to a final ratio of 1:10 vol/
vol (after correction for dilution by the hematocrit).
Constrictor responses were recorded over 8 min and
normalized to the maximum vasoconstriction induced
by KCl (% of KClmax =100%) [7,35].Statistical analysis
Continuous data are presented as mean±standard error
of mean (SEM), categorical data as absolute numbers.
Patient characteristics were compared using unpaired
t test (continuous data) and 2-tailed Fisher’s exact test
(categorical data). Mediator concentrations in particulate
debris and serum CRP were compared between patients
with and without DM using unpaired t test. Serum
troponin I and TIMI flow grading before and after stent
implantation, mediator concentrations in and vasocon-
strictor responses to coronary arterial and aspirate
plasma, minimal lumen diameter and the percent diam-
eter stenosis before, immediately after and 6 months
after stent implantation were compared between patients
with and without DM using 2-way repeated measures
ANOVA followed by Bonferroni’s post-hoc tests. Linear
regression analysis was calculated between the increase
in TNFα immediately after stent implantation and angio-
graphic diameter 6 months later in patients with and
without DM. All statistics were performed with SPSS
Statistics 19.0; SPSS Inc., Chicago, IL, USA. P<0.05 was
considered significant.Results
Patient characteristics (Table 1) and the vessel character-
istics (Table 2), respectively, did not differ between the
groups with and without DM (apart from their HbA1c-
value and antidiabetic medications by definition, body
weight and diuretics). TIMI flow was higher after stent
implantation, but not different between patients with
and without DM. Serum troponin I was increased after
stent implantation, but not different between groups
(Table 3). Troponin I after stent implantation exceeded
the proposed cutoff level of 0.15 μg/L, reflecting myone-
crosis [39], in 6 patients with and in 8 without DM.Volume and composition of plaques and particulate
debris
Plaque volume was comparable between patients with
and without DM, but the necrotic core was greater and
that of fibro-fatty tissue smaller in patients with DM.
(Figures 1A-B). The amount of released particulate deb-
ris in coronary aspirate from patients with DM was
greater than from those without DM, even when nor-
malized to stent volume, respectively (Figure 2A).
Table 1 Patient characteristics
With DM Without DM P-value
demographics
number 20 20 1.0
gender, female/male 0/20 0/20 1.0
age [years] 64±2 68±2 0.2
body height [cm] 174±1 173±1 0.5
body weight [kg] 89±2 83±2 0.04
risk factors/comorbidities
hypertension 20 20 1.0
BMI [kg/m2] 29.4±0.7 27.8±0.6 0.1
smoking 1 3 0.6
hypercholesterolemia 18 20 0.5
family history of CAD 6 5 1.0
hemodynamics
systolic blood pressure [mmHg] 129±6 134±3 0.5
diastolic blood pressure [mmHg] 65±3 66±2 0.6
heart rate [bpm] 66±2 66±3 0.9
laboratory analysis
total cholesterol [mmol/L] 4.5±0.3 4.5±0.2 0.8
HDL cholesterol [mmol/L] 1.0±0.1 1.0±0.1 0.9
LDL cholesterol [mmol/L] 2.5±0.2 2.7±0.2 0.4
CRP [mg/L] 5.6±0.9 4.8±1.0 0.6
triglycerides [mmol/L] 2.7±0.5 1.8±0.3 0.1
serum creatinine [μmol/L] 114.0±6.4 111.8±4.4 0.8
urea nitrogen [mmol/L] 8.0±1.2 7.7±0.6 0.9
eGFR [mL/min/1.73 m2] 60.1±2.9 59.7±3.0 0.9
HbA1c [%] 7.7±0.3 5.3±0.2 < 0.01
medication
ACE inhibitors 19 15 0.2
AT1-receptor antagonists 3 4 1.0
beta-blockers 19 18 1.0
calcium antagonists 3 1 0.6
statins 19 18 1.0
diuretics 18 10 0.01
antidiabetics: 16 0 < 0.01
metformin 13 0 0.05
glibenclamide 3 0 0.6
insulin 5 0 0.05
aspirin 20 20 1.0
clopidogrel 17 17 1.0
Continuous data are presented as mean±SEM, categorical data as absolute
numbers. Comparison between patients with and without DM by unpaired
t test (continuous data) and 2-tailed Fisher’s exact test (categorical data).
ACE = angiotensin-converting enzyme; AT1 = angiotensin II type 1; BMI = body
mass index; bpm = beats per minute; CAD = coronary artery disease; CRP = C
reactive protein; DM = diabetes mellitus; eGFR = estimated glomerular
filtration rate; HbA1c = hemoglobin A1c; HDL = high density lipoprotein;
LDL = low density lipoprotein.
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particulate debris and coronary aspirate plasma and
vasoconstrictor action of coronary aspirate plasma
Confirming the IVUS VH analysis, the total calcium con-
centration in particulate debris was not different between
patients with and without DM (Figure 2B). The concen-
trations of serotonin and TxB2 in particulate debris did
not differ between groups (Figures 3A-B). The concentra-
tion of TNFα in particulate debris of patients with DM
was higher than in those without DM (Figure 3C).
The total concentration of calcium in coronary aspir-
ate plasma was 2.78±0.14 mmol/L in patients with and
2.39±0.13 mmol/L in those without DM, respectively.
The concentrations of endothelin, epinephrine, norepin-
ephrine, and tissue factor in coronary aspirate plasma
were not different between patients with and without
DM and not altered by stent implantation. The concen-
trations of serotonin and TxB2 in coronary aspirate
plasma were increased after stent implantation, but not
differently between groups (Table 4). The concentration
of TNFα in coronary aspirate plasma was increased after
stent implantation in both groups, but more so in
patients with than in those without DM (Table 4).
As expected from the released soluble vasoconstrictor
substances, the coronary aspirate plasma induced com-
parable vasoconstriction in both groups (Figure 4).
Angiographic data of percent diameter stenosis at
6 months follow-up
Before stent implantation, the percent diameter of the
stenosis of the SVG did not differ between groups. Imme-
diately after stent implantation, the percent diameter of
the stenosis of the SVGs was reduced and not different be-
tween groups. Six months after stent implantation, the
percent diameter of stenosis of the SVGs was increased in
both groups, but more so in patients with than in those
without DM (see Table 5). The increase in TNFα immedi-
ately after stent implantation correlated with the angio-
graphic diameter reduction 6 months later in patients
with and without DM (r=0.69, P<0.05; Figure 5).
Discussion
In the present study, graft atherosclerosis of patients with
DM was more necrotic and released more particulate deb-
ris during stent implantation. Release of the vasocon-
strictor substances serotonin and TxB2 into the particulate
debris and coronary aspirate plasma was comparable be-
tween groups and induced a largely comparable vasocon-
strictor response ex vivo. In contrast, the release of the
inflammatory cytokine TNFα into the particulate debris
and coronary aspirate plasma was greater in patients with
DM, possibly reflecting the greater activity of the under-
lying atherosclerotic process and associated with greater
diameter reduction 6 months after stent implantation.
Table 2 Vessel characteristics
With DM Without DM P-value
saphenous vein bypass graft
graft-age [years] 9±2 12±1 0.1
target vessels
left anterior descending coronary
artery 5 6 1.0
left circumflex coronary artery 9 9 1.0
right coronary artery 6 5 1.0
lesion site
ostial 5 3 0.7
proximal 11 13 0.7
distal 4 4 1.0
lesion with thrombus 0 0 1.0
quantitative coronary angiography
stenosis diameter [%] 57±2 57±3 0.9
IVUS-analysis
MLA [mm2] 3.8±0.3 3.8±0.3 0.9
RLA [mm2] 10.2±0.9 10.6±1.0 0.8
plaque burden [%] 69.4±2.2 70.5±2.3 0.7
stent
stent diameter [mm] 3.7±0.1 3.7±0.1 0.6
stent length [mm] 20.4±1.1 23.1±1.3 0.1
maximal balloon deployment pressure
pressure [atm] 20.2±0.8 19.3±0.8 0.4
Continuous data are presented as mean±SEM, categorical data as absolute numbers. Comparison between patients with and without DM by unpaired t test
(continuous data) and 2-tailed Fisher’s exact test (categorical data). DM = diabetes mellitus; IVUS = intravascular ultrasound; LDL = low density lipoprotein;
MLA = minimal lumen cross-sectional area in the culprit segment; RLA = reference lumen area.
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and without DM undergoing elective stent implantation
into their stenotic SVGs. We identified more necrotic core
in plaque of SVG of patients with DM by IVUS imaging.
As expected from the greater volume fraction of necrotic
core, the plaque was more unstable [40] and stent im-
plantation induced more particulate debris release in
patients with than in those without DM.
Confirming our prior studies [7,8], the concentrations
of the vasoconstrictor substances serotonin and TxB2 in
coronary aspirate plasma were increased after stent im-
plantation in both groups, but not different between
groups. Thus, the coronary aspirate also induced a
largely comparable vasoconstrictor response ex vivo.Table 3 TIMI flow and serum troponin I before and after sten
With DM
Before stent implantation After stent
TIMI flow, n = 20 / 20 2.7 ± 0.1 3.0*
troponin I [μg/L], n = 20 / 20 0.08 ± 0.04 0.32 ±
Data are mean±SEM. Comparison by 2-way repeated measures ANOVA with Bonfer
mellitus; TIMI = thrombolysis in myocardial infarction.The release of serotonin, which is the main coronary
vasoconstrictor after stent implantation into SVGs, is
attributed to platelet activation during stent implant-
ation. Despite dual inhibition with aspirin and clopido-
grel, platelets still release major amounts of serotonin
[41]. In the presence of dual platelet inhibition, the re-
lease of TxB2, which potentiates the vasoconstriction to
serotonin [7,8], is not attributed to platelets, but to
macrophages in the atherosclerotic vascular wall [42,43],
possibly also obscures potential differential diabetics and
non-diabetics.
In contrast to serotonin and TxB2, the concentration
of TNFα in particulate debris and in coronary aspirate
plasma was higher in patients with than in those withoutt implantation
Without DM
implantation Before stent implantation After stent implantation
2.8 ± 0.1 3.0*
0.12* 0.04 ± 0.01 0.37 ± 0.12*
roni’s correction; *P<0.05 before vs. after stent implantation. DM = diabetes
Figure 1 SVG plaque volume (A) and composition (B) - Data are mean±SEM, comparison between patients with and without DM by
unpaired t tests. DM = diabetes mellitus.
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cells in the atherosclerotic vascular wall and associated
with plaque remodelling and facilitation of plaque rup-
ture and thrombus formation [44]. TNFα also potenti-
ates the vasoconstriction to serotonin [7,8]. In the
present study, we did not detect such a potentiation in
vasoconstriction. However, the difference in TNFα levels
between the patient groups (with versus without DM)Figure 2 Amount of released particulate debris (A) and calcium conce
amount of released particulate debris to stent volume in numbers in
and without DM by unpaired t tests. DM = diabetes mellitus.was quite small (1 pmol/L). In our prior study [7], how-
ever, we have determined the TNFα-mediated enhance-
ment of vasoconstriction with exogenous application of
25 pmol/l. Prior studies have already confirmed an asso-
ciation between systemic inflammation in atherosclerosis
and type 2 diabetes [20-22]. We detected a small, but
non-significant difference between patients with and
without DM with respect to TNFα-levels in coronaryntration per amount of particulate debris (B) – The normalized
inserts; data are mean±SEM, comparison between patients with
Figure 3 Concentrations of serotonin (A), TxB2 (B), and TNFα (C) per amount of particulate debris - Data are mean±SEM, comparison
between patients with and without DM by unpaired t tests. DM = diabetes mellitus; TxB2 = thromboxane B2, TNFα = tumor necrosis factor α.
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ference in systemic inflammation. In line with these ar-
terial TNFα data, peripheral venous serum CRP also
tended to be higher. Metformin may have an anti-
inflammatory effect by suppressing the production of
TNFα [45-47]. In the present study, the treatment with
metformin in diabetic patients was stopped before angi-
ography and paused for 48 h. We stratified the TNFα
concentrations in coronary arterial and aspirate plasma
of diabetic patients with respect to metformin use. The
TNFα concentrations in coronary arterial (with metfor-
min: 1.2±0.4 vs. without metformin: 1.1±0.6 pmol/L,
n=9/6) and aspirate plasma (with metformin: 2.2±1.1 vs.
without metformin: 2.1±0.9 pmol/L, n=9/6) did not dif-
fer. We have previously shown that in patients with a se-
vere stenosis in their SVG, the release of TNFα
correlates with the incidence of restenosis [6]. In the





catecholamines, n = 12 / 12
epinephrine [nmol/L] 0.4 ± 0.1
norepinephrine [nmol/L] 3.2 ± 0.8
endothelin [pmol/L], n = 15 / 16 1.4 ± 0.6
serotonin [μmol/L], n = 15 / 16 0.5 ± 0.2
thromboxane B2 [pmol/L], n = 15 / 16 46 ± 7
tissue factor [pmol/L], n = 15 / 16 8.6 ± 0.5
TNFα [pmol/L], n = 15 / 16 1.1 ± 0.3
Data are mean±SEM. Comparison by 2-way repeated measures ANOVA with Bonfer
vs. coronary aspirate plasma. DM = diabetes mellitus; TNFα = tumor necrosis factorincrease immediately after stent implantation with re-
stenosis 6 months later. In support of this notion, in the
present study, patients with DM had a higher TNFα in-
crease immediately after stent implantation and a greater
diameter stenosis of their stented SVG at 6 months later
than those without DM.
Conclusion
In conclusion, in patients with DM the greater plaque
instability with more particulate debris release appears
to account for their greater microvascular obstruction
immediately after stent implantation. In the present
study, such greater microvascular obstruction, which
would be expected from the greater release of particulate
debris, was not detected in TIMI flow or troponin I re-
lease, reflecting the effective protection with use of the
aspiration device. The higher concentration of TNFα in








0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1
3.7 ± 0.6 3.4 ± 0.9 4.1 ± 1.3
1.3 ± 0.5 1.9 ± 0.6 1.7 ± 0.6
0.9 ± 0.4† 0.4 ± 0.1 1.1 ± 0.5†
95 ± 9† 51 ± 8 82 ± 13†
8.7 ± 0.6 9.6 ± 1.0 8.8 ± 0.8
2.2 ± 0.7*, † 0.5 ± 0.2 1.1 ± 0.2†
roni’s correction; *P<0.05 with vs. without DM, †P<0.05 coronary arterial plasma
α.
Figure 4 Vasoconstrictor responses to coronary arterial plasma
before and to coronary aspirate plasma after stent
implantation – Detected on rat mesenteric arteries with intact
endothelium (+E) and denuded -E, respectively. Data are mean
±SEM, comparison between patients with and without DM and
before and after stent implantation by 2-way repeated measures
ANOVA with Bonferroni’s correction. DM = diabetes mellitus.
















Figure 5 Correlation between TNFα increase immediately after
stent implantation and percent diameter stenosis 6 months
later – Linear regression (black line) between the increase in
TNFα and percent diameter stenosis in patients with (filled
circle) and without (open circle) DM. TNFα = tumor necrosis
factor α.
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erosclerotic process and could potentially serve as a bio-
marker for the incidence and extent of restenosis [6,29].
Study limitations
Our study is limited to a small number of patients
undergoing elective PCI of their SVG and requires pro-
spective confirmation in larger cohorts of patients. Mor-
tality and the incidence of vascular complications are
increased in women after SVG stenting [48]. In our co-
hort including only male patients, we were not able to
evaluate gender-specific effects. The model of SVG dis-

















Data are mean±SEM. Comparison by 2-way repeated measures ANOVA with Bonfer
†P<0.05 immediately after vs. 6 months after stent implantation, ‡P<0.05 before vs.
mellitus.other factors not related to DM. The plaque composition
of SVG differs from that of native vessels [35,49-51].
Nevertheless, as in native coronary arteries, there was also
more necrotic core in SVG plaque of patients with DM, as
determined by VH based on IVUS imaging before stent
implantation. VH has not been validated for use in SVG,
and the lack of a clear interface between media and adven-
titia in SVG makes vessel volume measurements more
problematic than in native coronary arteries [35]. How-
ever, our most significant finding on the relation of
increased aspirate TNFα and restenosis was based on
quantitative angiography.
In the present study, we have focused on TNFα as a
prototype of inflammatory cytokines. However, also
other inflammatory mediators (IFN-γ, IL-1, IL-6) might
play a role in the systemic inflammatory process of ath-
erosclerosis in patients with DM, and their levels pos-
sibly also correlate with restenosis 6 months after stent











7†, § 1.30±0.17‡ 3.23±0.22* 3.15±0.24‡
†, ‡, § 60.84±4.31 3.01±0.7* 6.34±1.11†, ‡
roni’s correction; *P<0.05 before vs. immediately after stent implantation,
6 months after stent implantation, §P<0.05 with vs. without DM; DM = diabetes
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